Shanghai Domiray Biotechnology

Shanghai Domiray Biotechnology (officially Shanghai Duomirui Biotechnology) is a clinical-stage biopharmaceutical company specializing in the development of long-acting peptide and recombinant protein therapeutics. Founded in 2015 as a spin-off from the China State Institute of Pharmaceutical Industry (CSIPI) and now a subsidiary of Sinopharm, the company leverages its proprietary Lipidation-dimerization (LiDi) and Albumin Binding Domain (ABD) platforms to enhance the pharmacokinetic profiles of its drug candidates. Its pipeline includes DMR2301, a long-acting FGF21 analog for MASH, and several clinical-stage programs for diabetes, hypoglycemia, and osteoporosis. Domiray combines deep expertise in peptide engineering with the industrial resources of Sinopharm to address significant unmet medical needs in China and global markets.